Immunization with a novel HIV-1-Tat multiple-peptide conjugate induces effective immune response in mice

Peptides

Volumn 21, Issue 12, 2000, Pages 1839-1847

  Boykins, Robert A ^a   Ardans, Jeanette A ^b   Wahl, Larry M ^b   Lal, Renu B ^c   Yamada, Kenneth M ^b   Dhawan, Subhash ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

AIDS; HIV; HIV 1 Tat; Macrophages; Monocytes; Pathogenesis; Vaccine

Indexed keywords

ANTIBODY; PEPTIDE; TRANSACTIVATOR PROTEIN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; MASS SPECTROMETRY; MONOCYTE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VIRUS ACTIVATION; VIRUS PATHOGENESIS; WESTERN BLOTTING; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANTIVIRAL ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; PROTEIN DOMAIN; VACCINE PRODUCTION; VIRUS INACTIVATION; VIRUS INHIBITION; VIRUS ISOLATION;

EID: 0034531591     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(00)00334-X     Document Type: Article

References (38)

1. Differential modes for extracellular HIV1-Tat modulation of HIV infection
2. Identification of a novel domain of HIV tat involved in monocyte chemotaxis
3. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
4. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
5. Synthesis and construction of a novel multiple peptide conjugate system: Strategy for a subunit vaccine design
6. A short polypeptide domain of HIV-1-Tat protein mediates pathogensis
7. Why do we not have an HIV vaccine and how can we make one?
8. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
9. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat
10. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region
11. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 tat protein
12. The Tat protein of HIV-1 induces tumor necrosis factor (TNF)- production. Implications for HIV-1-associated neurological diseases
13. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge
14. HIV-1 infection alters monocyte interactions with human microvascular endothelial cells
15. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation
16. New prospects for the development of a vaccine against immunodeficiency virus type 1. An overview
17. HIV-1 Tat protein as a potential AIDS vaccine
18. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients
19. The exogenous transactivation activity of HIV-1 tat
20. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains
21. Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic
22. HIV-Tat protein activates c-Jun N-terminal kinase and activator protein-1
23. HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis
24. HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes
25. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression
26. Immunopathogenesis of HIV-1: Role of coreceptors and other pathogens in modulating HIV expression
27. Tat toxoid: Its potential role as an HIV vaccine
28. A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid
29. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection
30. Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells
31. Neurobiological aspects of human immunodeficiency virus infection: Neurotoxic mechanisms
32. Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures
33. Evaluation of a candidate human immunodeficiency virus type 1 [HIV-1] vaccine in macaques: Effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus
34. The role of HIV-1 activated leukocyte adhesion mechanisms and matrix metalloproteinase production in AIDS pathogenesis
35. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: A rationale for the use of Tat toxoid as an HIV-1 vaccine
36. Correlation between genetic and biological properties of biologically cloned HIV type 1 viruses representing subtypes A, B, and D
37. Genotypic and phenotypic characterization of HIV-1 patients with primary infection